Home › Viral Infections › Ohio › Cincinnati
Viral Infections clinical trials in Cincinnati, OH
4 studies for Viral Infections are looking for participants at sites in and around Cincinnati (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
RecruitingPhase 3
- University of Cincinnati Medical Center, Cincinnati
- University of Cincinnati College of Medicine (UC Holmes), Cincinnati
Donor-Derived Viral Specific T-cells (VSTs)
RecruitingPhase 1/2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Third Party Viral Specific T-cells (VSTs)
RecruitingPhase 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
About Viral Infections
Viruses cause familiar infections such as the common cold, but they also cause severe illnesses. Learn more about viral infections and their symptoms.
More about Viral Infections on MedlinePlus
Viral Infections trials in other cities
- Washington, DC11 studies
- Houston, TX7 studies
- Hialeah, FL6 studies
- Boston, MA6 studies
- Baltimore, MD5 studies
- Dallas, TX4 studies
- Atlanta, GA4 studies
- Miami, FL4 studies
- New York City, NY4 studies
- Columbus, OH4 studies
- Salt Lake City, UT3 studies
- Cleveland, OH3 studies
Other studies in Cincinnati
- Non-Small Cell Lung Cancer31 studies
- Cancer (all types)26 studies
- Breast Cancer24 studies
- Heart Failure22 studies
- Metastatic Cancer21 studies
- Colorectal Cancer20 studies
- Obesity20 studies
- Acute Myeloid Leukemia20 studies
- Prostate Cancer19 studies
- Ovarian Cancer18 studies
- Lung Cancer18 studies
- Multiple Myeloma17 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.